GlassScriptPhysician profile
Sara Knox Eakin
NPI 1477037042
$6,274.05
in general payments reported to CMS, 2019-2025
22 companies · $2,614 in 2025
The $2,614 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $985 · 2022: $823 · 2023: $775 · 2024: $1,077 · 2025: $2,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,808 · Travel and Lodging: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,808.10 |
| Travel and Lodging | $657.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,672.32 | 2021-2025 | |
| Enterra Medical, INC. | $1,275.13 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $621.13 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $405.70 | 2023-2025 | Tremfya, Stelara |
| Genzyme Corporation | $353.99 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $338.30 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $331.49 | 2023-2024 | Epclusa, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.72 | 2021-2025 | Xifaxan |
| Axonics, INC. | $195.31 | 2022 | |
| Novo Nordisk INC | $108.69 | 2022 | |
| Pfizer INC. | $108.35 | 2025 | |
| Mallinckrodt Hospital Products INC. | $96.19 | 2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $96.19 | 2025 | Iqirvo |
| Dexcom, INC. | $85.40 | 2025 | Dexcom G6 Transmitter |
| Janssen Scientific Affairs, LLC | $84.96 | 2024 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $47.32 | 2021 | |
| Nestle Healthcare Nutrition INC. | $35.68 | 2021 | |
| Celgene Corporation | $29.08 | 2021 | |
| Aimmune Therapeutics, INC. | $29.03 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $18.16 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.94 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Eakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.